Aerie Pharmaceuticals Inc represents values of innovation, dedication, and patient-centricity in the pharmaceutical industry. The company aims to develop and commercialize groundbreaking therapies that address unmet needs in ophthalmology. With a strong focus on research and development, Aerie Pharmaceuticals is committed to improving the lives of individuals suffering from eye diseases. By employing cutting-edge technologies and collaborating with experts, Aerie strives to advance scientific understanding and deliver effective treatments. The company's corporate philosophy emphasizes integrity, teamwork, and a mission-driven approach to revolutionize eye care. Aerie Pharmaceuticals Inc continually strives to make a positive impact on patients' vision health.

Aerie Pharmaceuticals Inc primarily operates and is present in various countries and regions worldwide. The company has a global presence, with its main focus on the United States, where it is headquartered. Additionally, Aerie Pharmaceuticals Inc has commercial operations and partnerships across countries such as Canada, Europe (including the United Kingdom and Germany), Latin America, and Asia-Pacific regions. By expanding its reach internationally, Aerie Pharmaceuticals Inc aims to provide its innovative ophthalmic products and therapies to a broader patient population and improve global eye health.

Aerie Pharmaceuticals Inc has achieved several significant milestones. The company successfully developed and gained FDA approval for Rocklatan®, a once-daily eye drop for the treatment of glaucoma and ocular hypertension. Aerie also achieved positive Phase 3 results for Rhopressa®, another innovative eye drop for lowering intraocular pressure. Furthermore, Aerie Pharmaceuticals Inc expanded its product portfolio through strategic collaborations and acquisitions, enhancing its research and development capabilities. With these accomplishments, Aerie Pharmaceuticals Inc has established itself as a leading pharmaceutical company specializing in the treatment of eye disorders, making significant advancements in the ophthalmic industry.

Aerie Pharmaceuticals Inc is a renowned pharmaceutical company that specializes in the discovery, development, and commercialization of innovative therapies for treating eye diseases. Established in 2005, Aerie Pharmaceuticals has a strong commitment to improving patients' lives by addressing unmet medical needs in ophthalmology. The company has achieved significant milestones, including the approval and launch of their first product, Rhopressa®, a treatment for glaucoma. With a focus on developing cutting-edge advancements in ocular health, Aerie Pharmaceuticals continues to expand its portfolio and is dedicated to enhancing vision care worldwide.

The main competitors of Aerie Pharmaceuticals Inc in the market are Alcon, Allergan, and Novartis.

Aerie Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

Aerie Pharmaceuticals Inc operates under a distinct business model in the pharmaceutical industry. They focus on researching, developing, and commercializing innovative treatments for eye diseases. The company primarily specializes in glaucoma management and ocular surface diseases. Aerie Pharmaceuticals Inc aims to provide safe and effective therapeutics to improve patients' eye health and vision. With a strong dedication to scientific excellence and patient-centered approach, the company continues to strive for breakthroughs in the field of ophthalmology.

Aerie Pharmaceuticals KGV ir -47,79.

Aerie Pharmaceuticals KUV ir 3,03.

AlleAktien kvalitātes vērtējums Aerie Pharmaceuticals ir 5/10.

gaidāmā Aerie Pharmaceuticals apgrozījums ir 233,03 milj. USD.

gaidāmā Aerie Pharmaceuticals peļņa ir -14,79 milj. USD.

Aerie Pharmaceuticals Inc. is a US pharmaceutical company specialized in research, development, and marketing of drugs for the treatment of eye diseases. The company is headquartered in Durham, North Carolina and was founded in 2005. The company's activities can be divided into two main areas: research and development, and sales and marketing. In the research and development area, Aerie Pharmaceuticals focuses on discovering and developing innovative therapeutics for the treatment of glaucoma and other eye diseases. One of the company's main products is Rhopressa (Netarsudil), a unique medication used to lower intraocular pressure in patients with glaucoma or ocular hypertension. Rhopressa belongs to a new class of drugs known as Rho kinase inhibitors, which have shown promising results in the treatment of eye diseases. In addition to Rhopressa, Aerie Pharmaceuticals has also developed a medication called Roclatan, a combination of Netarsudil and Latanoprost, used for the treatment of glaucoma and ocular hypertension. Both medications have the potential to lower intraocular pressure by up to 35%, significantly reducing the risk of vision loss in glaucoma patients. In the sales and marketing area, Aerie Pharmaceuticals works closely with physicians, pharmacies, and hospitals to position its products in the market and provide patients with access to the latest treatment options. The company has built a wide network of distribution partners and utilizes online platforms to promote its products and generate awareness. Aerie Pharmaceuticals follows a strategy of vertical integration, conducting both research and development and the marketing of its products in-house. This allows the company to bring its products to market faster and more effectively, offering its customers a higher value proposition. Overall, Aerie Pharmaceuticals is successful in the field of ophthalmology and has established itself as a key player in the industry. The company relies on innovation, research and development, and utilizes its expertise in sales and marketing to provide its customers with the best possible products and services.

Aerie Pharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Aerie Pharmaceuticals vai uzņēmums nedod dividendes.

Aerie Pharmaceuticals ISIN ir US00771V1089.

Aerie Pharmaceuticals WKN ir A1W7RL.

Aerie Pharmaceuticals simbols ir AERI.

Pēdējo 12 mēnešu laikā Aerie Pharmaceuticals maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Aerie Pharmaceuticals plāno maksāt dividendes 0 USD apmērā.

Aerie Pharmaceuticals pašreizējā dividendu rentabilitāte ir .

Aerie Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Aerie Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Aerie Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Aerie Pharmaceuticals apmērā 0 USD, kas tika izmaksāta 15.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 15.07.2024..

Pēdējās dividendes izmaksa notika 15.07.2024..

Gadā 2023, Aerie Pharmaceuticals izmaksāja 0 USD dividendes.

Aerie Pharmaceuticals dividendes tiek izmaksātas USD.